Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 21%
Buy 32%
Hold 47%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is a strong investment candidate due to its strong performance and growth drivers, as well as its focus on sustainability and expansion into new markets. However, challenges with supplier shortages and market conditions may impact stock performance in the short term. The company's differentiation from competitors and potential for profitability growth make it an attractive long-term investment option.

Bears say

Tandem Diabetes Care is a technology company with a strong potential for consistent double-digit revenue growth due to its innovative insulin pump designs and upcoming product pipeline, however, there are potential downside risks such as slower-than-expected market expansion and competitive threats that may limit its ability to take market share. Additionally, dependence on third-party suppliers and lack of reimbursement from payers could impact Tandem's growth and profitability, and there is a risk of product recalls. Despite these risks, the company's current fundamental setup and upcoming OUS renewal cycle make it an attractive investment opportunity, with room for multiple expansions and potential for a re-rating of 1-1.5x turns above its median 1.7x target. It is important to monitor the company's execution over the next few years to determine if it can meet growth and profitability targets.

TNDM has been analyzed by 19 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 32% recommend Buy, 47% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 19 analysts, TNDM has a Buy consensus rating as of Aug 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.